Morgan Stanley lowered the firm’s price target on HCA Healthcare (HCA) to $406 from $427 and keeps an Equal Weight rating on the shares. While the firm says it anticipated noise due to hurricanes, the “bigger surprise” was a 2025 view for EBITDA and EPS below the Street that reversed a period of strong beat/raises, according to the firm, which is “tempted by the 9% pullback Friday,” but thinks the stock may be in a for a period of consolidation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target lowered to $420 from $475 at KeyBanc
- Judge blocks Tapestry-Capri deal, Centene reports Q3 beat: Morning Buzz
- Morning Movers: Capri sinks after judge blocks planned takeover by Tapestry
- HCA Healthcare Reports Strong Q3 2024 Results
- HCA Healthcare backs FY24 adjusted EPS view $21.60-$22.80, consensus $22.62